Tonix Pharmaceuticals Holding Corp. has received $-0.16 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.19 while the top line estimate is $-0.13 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 77.46%.
Tonix Pharmaceuticals Holding Corp. reported better than expected with a surprise EPS of 23.53% or $0.08 during its most recent quarterly earnings. The Actual EPS was $-0.26 compared to the Estimated EPS of $-0.34. New York based Tonix Pharmaceuticals Holding Corp. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 03, 2017.
In the last quarter, Tonix Pharmaceuticals Holding Corp. reported Annual Earnings of $-0.26. Based on the filings, last years Annual Earnings was, $-2.86. In the last Quarter, TNXP reported a surprise Earnings per Share of 23.53% . The consensus estimate for current quarter is $-0.16 and for the current fiscal year, the estimate is $-1.46. For the Next fiscal year, the estimate is $-0.4 based on the consensus.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.028 points or 4.94% at $0.539 with 2,079,340 shares getting traded. Post opening the session at $0.55, the shares hit an intraday low of $0.5201 and an intraday high of $0.5848 and the price was in this range throughout the day. The company has a market cap of $21 million and the number of outstanding shares has been calculated to be 39,200,000 shares. The 52-week high of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is $4.98 and the 52-week low is $0.352.
Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.